{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05222191",
            "orgStudyIdInfo": {
                "id": "12672"
            },
            "organization": {
                "fullName": "Indiana Institute for Medical Research",
                "class": "OTHER"
            },
            "briefTitle": "Spironolactone in CKD Enabled by Chlorthalidone: PILOT",
            "officialTitle": "Spironolactone in Chronic Kidney Disease Enabled by Chlorthalidone: A Pilot Randomized Control Trial",
            "acronym": "SPICE PILOT",
            "therapeuticArea": [
                "Nephrology and Renal Diseases",
                "Cardiovascular"
            ],
            "study": "spironolactone-in-ckd-enabled-by-chlorthalidone-pilot"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-02-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-12-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-12-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-01-18",
            "studyFirstSubmitQcDate": "2022-02-01",
            "studyFirstPostDateStruct": {
                "date": "2022-02-03",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-08-11",
            "lastUpdatePostDateStruct": {
                "date": "2023-08-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Rajiv Agarwal",
                "investigatorTitle": "Principal Investigator",
                "investigatorAffiliation": "Indiana Institute for Medical Research"
            },
            "leadSponsor": {
                "name": "Indiana Institute for Medical Research",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "Highly prevalent among patients with chronic kidney disease (CKD) and poorly controlled blood pressure (BP), is a modifiable risk factor to abrogate both kidney failure progression and cardiovascular (CV) disease. Spironolactone (SPL), a mineralocorticoid receptor antagonist, is widely used to treat resistant hypertension, however one of the most common side effects is an increase of serum potassium (K). This side effect occurs frequently in those who suffer from CKD. Alternatively, chlorthalidone (CTD) is a thiazide-like diuretic used for treating hypertension and decreases serum K. In this pilot study, our goal is to assess whether the combination of SPL and CTD can improve BP control, while also reducing the risk of hyperkalemia over a period of 12 weeks. We hypothesize that among patients with CKD and poorly controlled hypertension, compared to SPL and placebo, treatment over 12 weeks with CTD will counter the hyperkalemia effect of SPL, and therefore the combination of SPL with CTD will result in a lower BP. This pilot study will be performed at Richard L. Roudebush VA in Indianapolis, Indiana.",
            "detailedDescription": "This is a placebo-controlled, double-blind, randomized controlled trial of spironolactone (SPL) and chlorthalidone (CTD) in patients with CKD and poorly controlled hypertension"
        },
        "conditionsModule": {
            "conditions": [
                "Renal Insufficiency",
                "Chronic Hypertension"
            ],
            "keywords": [
                "Spironolactone",
                "Chlorthalidone",
                "Chronic Kidney Disease",
                "Hypertension",
                "Thiazide Diuretic",
                "Potassium Sparring Diuretic"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 24,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Spironolactone + Placebo",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Subjects with stage 3B/4 chronic kidney disease and poorly controlled hypertension will be randomized into two groups: one receiving spironolactone and placebo and one receiving spironolactone and chlorthalidone. At randomization, subjects will begin at 25 mg spironolactone and 6.25 mg placebo/chlorthalidone daily.",
                    "interventionNames": [
                        "Drug: Spironolactone",
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Spironolactone + Chlorthalidone",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects with stage 3B/4 chronic kidney disease and poorly controlled hypertension will be randomized into two groups: one receiving spironolactone and placebo and one receiving spironolactone and chlorthalidone. At randomization, subjects will begin at 25 mg spironolactone and 6.25 mg placebo/chlorthalidone daily.",
                    "interventionNames": [
                        "Drug: Spironolactone",
                        "Drug: Chlorthalidone"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Spironolactone",
                    "description": "Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).",
                    "armGroupLabels": [
                        "Spironolactone + Chlorthalidone",
                        "Spironolactone + Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Chlorthalidone",
                    "description": "Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).",
                    "armGroupLabels": [
                        "Spironolactone + Chlorthalidone"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Study drugs will be increased if goal blood pressure is not achieved and/or serum potassium is not in safe clinical range (dosage of chlorthalidone/placebo not to exceed 25 mg daily; dosage of spironolactone not to exceed 50 mg daily).",
                    "armGroupLabels": [
                        "Spironolactone + Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change in Systolic Automated Office Blood Pressure from baseline to 12 weeks between arms",
                    "timeFrame": "Baseline to 12 Weeks"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Change in logarithmically transformed albumin/creatinine ratio from baseline to 12 weeks between arms",
                    "timeFrame": "Baseline to 12 Weeks"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age greater than 18 years.\n2. GFR estimated by CKD-EPI formula \\< 45 ml/min/1.73 m2 but \u2265 15 mL/min/1.73 m2 using IDMS-calibrated creatinine.\n3. Hypertension. Using AOBP monitoring, BP of \u2265 130/80 mmHg.\n4. Treatment with antihypertensive drugs: This would require the use of at least one antihypertensive drug. One of the drugs should be either an ACE inhibitor or ARB or a beta-blocker at the time of randomization.\n5. Serum K 3.5 to 5.2 mEq/L at the time of randomization. In patients with eGFR \\< 45 ml/min/1.73 m2 and serum K \\> 5.2 mEq/L\n\nExclusion Criteria:\n\n1. Use of spironolactone, eplerenone, amiloride, triamterene, thiazides, or thiazide-like drugs or the use of K supplements or K binders in the previous 12 weeks.\n2. Expected to receive renal replacement therapy within the next 6 months.\n3. Myocardial infarction, heart failure hospitalization, or stroke \u2264 12 weeks prior to randomization.\n4. Pregnant or breastfeeding women or women who are planning to become pregnant or those not using a reliable form of contraception (oral contraceptives. condoms and diaphragms will be considered reliable).\n5. Known hypersensitivity to thiazide or spironolactone.\n6. Clinic AOBP \\<110 mmHg systolic at their first visit",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "19 Years",
            "maximumAge": "110 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Rajiv Agarwal, MD",
                    "role": "CONTACT",
                    "phone": "317-988-2241",
                    "email": "ragarwal@iu.edu"
                },
                {
                    "name": "Timothy l Ramsey, MS/MBA",
                    "role": "CONTACT",
                    "phone": "317-988-9544",
                    "email": "timothy.ramsey2@va.gov"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Rajiv Agarwal, MD",
                    "affiliation": "Indiana Institute for Medical Research; Roudebush VA Medical Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Richard L Roudebush VA Medical Center",
                    "status": "RECRUITING",
                    "city": "Indianapolis",
                    "state": "Indiana",
                    "zip": "46202",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Timothy l ramsey, ms",
                            "role": "CONTACT",
                            "phone": "317-988-9544",
                            "email": "timothy.ramsey2@va.gov"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.76838,
                        "lon": -86.15804
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000051437",
                    "term": "Renal Insufficiency"
                },
                {
                    "id": "D000006973",
                    "term": "Hypertension"
                }
            ],
            "ancestors": [
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000007674",
                    "term": "Kidney Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10698",
                    "name": "Kidney Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10024",
                    "name": "Hypertension",
                    "asFound": "Hypertension",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26718",
                    "name": "Renal Insufficiency",
                    "asFound": "Renal Insufficiency",
                    "relevance": "HIGH"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002752",
                    "term": "Chlorthalidone"
                },
                {
                    "id": "D000013148",
                    "term": "Spironolactone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000451",
                    "term": "Mineralocorticoid Receptor Antagonists"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000062865",
                    "term": "Diuretics, Potassium Sparing"
                },
                {
                    "id": "D000004232",
                    "term": "Diuretics"
                },
                {
                    "id": "D000045283",
                    "term": "Natriuretic Agents"
                },
                {
                    "id": "D000000959",
                    "term": "Antihypertensive Agents"
                },
                {
                    "id": "D000049993",
                    "term": "Sodium Chloride Symporter Inhibitors"
                },
                {
                    "id": "D000049990",
                    "term": "Membrane Transport Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M15943",
                    "name": "Spironolactone",
                    "asFound": "Pacing",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7411",
                    "name": "Diuretics",
                    "relevance": "LOW"
                },
                {
                    "id": "M5993",
                    "name": "Chlorthalidone",
                    "asFound": "1.3",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3797",
                    "name": "Mineralocorticoid Receptor Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M11871",
                    "name": "Mineralocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M30025",
                    "name": "Diuretics, Potassium Sparing",
                    "relevance": "LOW"
                },
                {
                    "id": "M4277",
                    "name": "Antihypertensive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M26152",
                    "name": "Sodium Chloride Symporter Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "NaAg",
                    "name": "Natriuretic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AnAg",
                    "name": "Antihypertensive Agents"
                }
            ]
        }
    },
    "hasResults": false
}